Organization
Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
1 abstract
Abstract
Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study.Org: University of Insubria, Varese, Italy, Hematology Unit, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy, Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom, Mayo Clinic Florida, Jacksonville, FL, The Richard T. Silver, M.D. Myeloproliferative Neoplasms Center, Division of Hematology and Oncology, Cornell Medicine, New York, NY,